Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HCWB 
HCW Biologics Inc (HCWB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HCWB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35
1 Year Target Price $35
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.03% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.95M USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 1 | Beta 0.67 | 52 Weeks Range 2.77 - 62.40 | Updated Date 08/29/2025 |
52 Weeks Range 2.77 - 62.40 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -16.41 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate 1.8 | Actual -0.9 |
Profitability
Profit Margin - | Operating Margin (TTM) -52886.67% |
Management Effectiveness
Return on Assets (TTM) -30.41% | Return on Equity (TTM) -27725.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16570520 | Price to Sales(TTM) 15.55 |
Enterprise Value 16570520 | Price to Sales(TTM) 15.55 | ||
Enterprise Value to Revenue 19.9 | Enterprise Value to EBITDA -3.63 | Shares Outstanding 2151610 | Shares Floating 1135661 |
Shares Outstanding 2151610 | Shares Floating 1135661 | ||
Percent Insiders 27.3 | Percent Institutions 1 |
Upturn AI SWOT
HCW Biologics Inc
Company Overview
History and Background
HCW Biologics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing novel immunotherapies to combat age-related diseases. It was founded to address unmet medical needs related to chronic inflammation and impaired tissue repair.
Core Business Areas
- Immunotherapies: Development of novel immunotherapies targeting age-related diseases and chronic inflammation.
- TOW platform: Utilizing the TOWeR (Tissue-specific Orientated multi-effector Warfare) platform to develop therapeutic candidates.
- Drug Discovery: Discovery and preclinical development of novel therapeutic candidates.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and drug development. The organizational structure is typical of a clinical-stage biopharmaceutical company with departments focused on research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- HCW9218: An investigational drug targeting age-related diseases. Currently in clinical trials. Market share is currently 0% as the product is not yet approved. Competitors include companies developing similar therapies for age-related diseases, such as those targeting senescent cells.
- HCW9215: An investigational drug being developed for cancer immunotherapy. Currently in preclinical studies. Market share is currently 0% as the product is not yet approved. Competitors include major pharmaceutical companies with established immuno-oncology drugs like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with increasing demand for novel therapies for age-related diseases and cancer. Innovation and regulatory approvals are key drivers.
Positioning
HCW Biologics Inc is positioned as an innovator in the development of immunotherapies for age-related diseases, leveraging its proprietary TOWeR platform. Their competitive advantage lies in the unique mechanism of action of their therapeutic candidates.
Total Addressable Market (TAM)
The total addressable market for age-related disease therapies is estimated to be worth billions of dollars. HCW Biologics Inc. is positioned to capture a portion of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary TOWeR platform
- Novel therapeutic candidates
- Experienced management team
Weaknesses
- Limited financial resources
- Clinical trial risks
- Dependence on successful development
Opportunities
- Growing demand for age-related disease therapies
- Potential for strategic partnerships
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure in clinical trials
Competitors and Market Share
Key Competitors
- LLY
- NVO
- SNY
Competitive Landscape
HCW Biologics Inc. faces intense competition from established pharmaceutical companies with greater resources. Its advantage lies in its innovative TOWeR platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early-stage clinical development. No revenue growth to report.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives include advancing HCW9218 through clinical trials and exploring strategic partnerships.
Summary
HCW Biologics Inc. is a high-risk, high-reward clinical-stage company. Its strengths lie in its innovative TOWeR platform and novel therapeutic candidates. It needs to secure additional funding and achieve positive clinical trial results. Its long-term success depends on the success of its clinical programs and ability to navigate regulatory hurdles and competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HCW Biologics Inc
Exchange NASDAQ | Headquaters Miramar, FL, United States | ||
IPO Launch date 2021-07-20 | Founder, CEO, Director & Secretary Dr. Hing C. Wong Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.hcwbiologics.com |
Full time employees 36 | Website https://www.hcwbiologics.com | ||
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.